INVIZYNE TECHNOLOGIES INC (IZTC) Stock Price & Overview
NASDAQ:IZTC • US4618741098
Current stock price
The current stock price of IZTC is 16.5 USD. Today IZTC is up by 6.45%. In the past month the price increased by 50%.
IZTC Key Statistics
- Market Cap
- 134.145M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -0.25
- Dividend Yield
- N/A
IZTC Stock Performance
IZTC Stock Chart
IZTC Technical Analysis
ChartMill assigns a technical rating of 5 / 10 to IZTC.
IZTC Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to IZTC. Both the profitability and financial health of IZTC have multiple concerns.
IZTC Earnings
IZTC Forecast & Estimates
IZTC Groups
Sector & Classification
IZTC Financial Highlights
Over the last trailing twelve months IZTC reported a non-GAAP Earnings per Share(EPS) of -0.25. The EPS decreased by -46.01% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -57.25% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
IZTC Ownership
IZTC Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.04 | 368.381B | ||
| AMGN | AMGEN INC | 15.4 | 189.472B | ||
| GILD | GILEAD SCIENCES INC | 15.98 | 175.4B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.29 | 114.717B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.92 | 78.668B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 42.19 | 41.749B | ||
| INSM | INSMED INC | N/A | 30.759B | ||
| NTRA | NATERA INC | N/A | 28.033B | ||
| BIIB | BIOGEN INC | 11.34 | 26.756B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.76 | 23.245B | ||
| MRNA | MODERNA INC | N/A | 20.695B | ||
| EXAS | EXACT SCIENCES CORP | 341.33 | 19.805B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.443B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About IZTC
Company Profile
Invizyne Technologies Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Monrovia California, California and currently employs 29 full-time employees. The company went IPO on 2024-11-13. Invizyne Technologies, Inc. is a biotechnology, pre-revenue, development stage company. The firm's cell-free technology expands its ability to perform enzyme-based conversions, guiding towards sustainable biomanufacturing. The firm is primarily engaged in the development of the SimplePath platform. Its SimplePath platform consists of a series of enzyme based biomanufacturing systems that leverage natural processes to perform complex chemical conversions that convert a starting material into a desired end-product. Each SimplePath system is composed of one or more modules which consist of one or more enzymes that work together to perform a defined biocatalytic conversion. The company can provide solutions for natural ingredients (cannabinoids, flavor enhancers for food and beverage products, fragrances, nutraceuticals, organic compounds), pharmaceuticals (natural products with therapeutic properties) and chemicals (commodity chemicals, specialty chemicals, biofuels).
Company Info
IPO: 2024-11-13
INVIZYNE TECHNOLOGIES INC
750 Royal Oaks Drive, Suite 106
Monrovia California CALIFORNIA US
Employees: 29
Phone: 16264151488
INVIZYNE TECHNOLOGIES INC / IZTC FAQ
What does IZTC do?
Invizyne Technologies Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Monrovia California, California and currently employs 29 full-time employees. The company went IPO on 2024-11-13. Invizyne Technologies, Inc. is a biotechnology, pre-revenue, development stage company. The firm's cell-free technology expands its ability to perform enzyme-based conversions, guiding towards sustainable biomanufacturing. The firm is primarily engaged in the development of the SimplePath platform. Its SimplePath platform consists of a series of enzyme based biomanufacturing systems that leverage natural processes to perform complex chemical conversions that convert a starting material into a desired end-product. Each SimplePath system is composed of one or more modules which consist of one or more enzymes that work together to perform a defined biocatalytic conversion. The company can provide solutions for natural ingredients (cannabinoids, flavor enhancers for food and beverage products, fragrances, nutraceuticals, organic compounds), pharmaceuticals (natural products with therapeutic properties) and chemicals (commodity chemicals, specialty chemicals, biofuels).
Can you provide the latest stock price for INVIZYNE TECHNOLOGIES INC?
The current stock price of IZTC is 16.5 USD. The price increased by 6.45% in the last trading session.
Does IZTC stock pay dividends?
IZTC does not pay a dividend.
What is the ChartMill technical and fundamental rating of IZTC stock?
IZTC has a ChartMill Technical rating of 5 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
Can you provide the sector and industry classification for INVIZYNE TECHNOLOGIES INC?
INVIZYNE TECHNOLOGIES INC (IZTC) operates in the Health Care sector and the Biotechnology industry.